Apellis Pharmaceuticals, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; October 2, 2023 deadline Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Apellis Pharmaceuticals,...

APLS Stockholders Should Contact Robbins LLP for Information About the Class Action Involving Apellis Pharmaceuticals, Inc. SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action against Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) on behalf of persons or...

APLS Stock News: Investors with Significant Losses in Apellis Pharmaceuticals, Inc. Should Contact Robbins LLP About Recovery SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action against Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) on behalf of persons or...

Apellis Pharmaceuticals, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; October 2, 2023 deadline Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 09, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Apellis Pharmaceuticals, Inc....

Apellis Pharmaceuticals, Inc. (APLS) Investor Alert: Robbins LLP Reminds Shareholders of Class Action Against Apellis Pharmaceuticals, Inc. SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action against Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) on behalf of persons and...